Aperiomics, a Sterling, Va.-based biotech company combining advancements in science, technology, closed a Series A funding round totaling $1.8m.
The round was led by VentureSouth with participation from Pipeline Angels, Propel(x) and high net worth individuals.
The company intends to use the funds to increase the number of patients they serve and clinicians they partner with, and make major investments in research and development.
Led by Dr. Crystal Icenhour, CEO, Aperiomics identifies every bacterium, virus, fungus, and parasite known to modern science through its Deep Shotgun Metagenomic Sequencing process.
The Xplore-PATHOSM Test combined advanced DNA testing, big data and infectious disease expertise to identify the root cause of infectious diseases. Given this, by offering unbiased insight, healthcare providers can prescribe precise treatments for specific conditions and offer improved care to patients.
The company recently expanded into a brand new 4,700 square foot facility in Sterling, Virginia and are constructing an on-site laboratory facility to be completed and certified in the coming months.